ArticleJournal of cancer research and clinical oncology2010
Clinical significance of pAKT and CD44v6 overexpression with breast cancer.
Article in Journal of cancer research and clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis.Journal of orthopaedic surgery and research · 2016Pooled it
- The prognostic value of phosphorylated Akt in breast cancer: a systematic review.Scientific reports · 2015Pooled it
- CD44 in Bladder Cancer.Cancers · 2024Review
- CD44v6 downregulation as a prognostic factor for distant recurrence in resected stage I lung adenocarcinomas.Clinical and experimental medicine · 2023Article
- The clinical significance of CD44v6 in malignant and benign primary bone tumors.BMC musculoskeletal disorders · 2023Article
- Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook.Frontiers in endocrinology · 2022Review
- Article
- Article
- Prognostic value of CD44v6 expression in breast cancer: a meta-analysis.OncoTargets and therapy · 2018Article
- Understanding the role of CD44V6 in ovarian cancer.Oncology letters · 2017Article
- Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance.Frontiers in oncology · 2016Article
- Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.Stem cells translational medicine · 2015Review
- Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts.Medical oncology (Northwood, London, England) · 2015Article
- Expression and association of CD44v6 with prognosis in T2-3N0M0 esophageal squamous cell carcinoma.Journal of thoracic disease · 2014Article
- CD44 is prognostic for overall survival in the NCI randomized trial on breast conservation with 25 year follow-up.Breast cancer research and treatment · 2014Article
- Article
- Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2012Article
- Expression of CD44v6 and Its Association with Prognosis in Epithelial Ovarian Carcinomas.Pathology research international · 2012Article
- Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice.PloS one · 2010Article
- Computational challenges, tools, and resources for analyzing co- and post-transcriptional events in high throughput.Wiley interdisciplinary reviews. RNAReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCD44v6 contributes to apoptosis resistance and metastasis via upregulated activity of the PI3K/AKT pathway. The purpose of this study was to investigate the expression patterns and predictive value of phosphorylated AKT (pAKT) and CD44v6 in breast cancer tissues.
methodsExpression of pAkt and CD44v6 protein was detected using immunohistochemistry in breast cancer tissues and lymph node tissues in 98 patients. The correlation between the expression of pAkt, CD44v6 and other disease-related characteristics was investigated. The prognostic value of pAKT and CD44v6 overexpression for overall survival (OS) and disease free survival (DFS) was determined.
results37 cases (37.8%) were observed as positive for pAkt expression, and 38 cases (38.8%) for CD44V6 overexpression. Staining was positive for pAKT in 20 of 38 (52.6%) CD44v6(+) and 17 of 60 (28.3%) CD44v6(-) (P = 0.016). A progressively increased trend of CD44v6 overexpression was observed from node(-) primary breast cancer tissues to node(+) primary cancer tissues to node(+) lymph tissues (P = 0.000). In univariate analysis lymph node status, pAKT and CD44V6 were significantly associated with a decreased OS and DFS. Multivariate analysis revealed that CD44v6 status was associated with a reduced OS (P = 0.003), and pAKT and CD44v6 with a shorter DFS (P = 0.012 and 0.016, respectively).
conclusionsOur data suggested that there had an intensive relationship between pAKT and CD44v6 expression in breast cancer tissues. The overexpression of CD44v6 was an independent prognostic marker for predicting OS and DFS of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.